Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SEARCH Ends Badly For Simvastatin 80 Mg; FDA Restricts Use To Existing Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

New clinical trial data and adverse event reports show high-dose simvastatin-containing products have a greater risk for muscle toxicity than other statins, the agency concludes.
Advertisement

Related Content

AERS Database Cannot Determine Adverse Event Incidence, FDA Says In Rejecting Statin Label Warning
Time, And Price, Are Right To Prescribe Statins To the Masses
Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends
Pharmacists, HIT Can Be Key To Successful Rx Care In ACO Model
FDA Cmte. Likes Vytorin Safety In SHARP, But Worries About Dose Escalation
Merck's Juvisync Becomes First Fixed-Dose Diabetes/Cholesterol Treatment
Merck's Juvisync Becomes First Fixed-Dose Diabetes/Cholesterol Treatment
Avandia REMS Requires Doctors To Tell Patients About Actos’ CV Safety
Avandia REMS Requires Doctors To Tell Patients About Actos’ CV Safety

Topics

Advertisement
UsernamePublicRestriction

Register

PS072481

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel